Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Polycythemia Vera: early-phase trial registry
10 of 23 indexed Polycythemia Vera trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 10 currently recruiting · #724 of 28,707 conditions by registered trial count
Polycythemia Vera: 23 US clinical trials tracked, 10 recruiting.
Polycythemia Vera is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition polycythemia-vera
OPEN 10 | RECR 43% | LATE 5 | EARLY 14 | RANK #724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Cigarette Smoking (43% recruiting · 46 trials)
Polycythemia Vera lists 10 open slots (43% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Polycythemia Vera on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Polycythemia Vera is recruiting above its size-band peers.
10 of 23 indexed trials (43.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Polycythemia Vera trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 3 of 23 trials (13%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most Polycythemia Vera trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 23 trials that report a genuine target (sentinel values excluded). 15 of those (65.2%) plan for fewer than 100 participants.
-
Polycythemia Vera research is mostly interventional.
19 interventional and 4 observational studies make up this index (82.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MPN Research Foundation
NCT07362225
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
NCT07203768
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme
NCT06351631
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Italfarma
NCT06093672
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
NCT06661915
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Massachusetts General Hospital
NCT04644211
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
NCT06063486
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
NCT05123365
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT04282187
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
NCT06218628
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Protagonist Therapeutics
NCT05210790
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
NCT05481151
Study to Assess SLN124 in Patients With Polycythemia Vera
Silence Therapeutics
NCT05499013
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Protagonist Therapeutics
NCT06033586
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03289910
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
Terrence J Bradley, MD
NCT04262141
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Incyte Corporation
NCT00509899
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms
Eli Lilly and Company
NCT01520220
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
NCT02493530
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Cephalon
NCT00586651
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
NCT00047190
Familial Myeloproliferative Disorders
Icahn School of Medicine at Mount Sinai
NCT00666289
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
National Institutes of Health Clinical Center (CC)
NCT00433862
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 8 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Polycythemia Vera records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Polycythemia Vera trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Polycythemia Vera page
23 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Polycythemia Vera trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Polycythemia Vera trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Polycythemia Vera condition card totals 23 registered trials; most-linked intervention Ruxolitinib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.